Been watching Regeneron's earnings closely, and there's an interesting dynamic playing out with their drug portfolio. The real story here isn't just about one product—it's how they're managing a transition while building new growth engines.

So here's what caught my attention. Eylea has been their cash cow for years, but it's facing real pressure from competition. The company saw that coming and developed Eylea HD, the higher-dose version. The uptake has been surprisingly strong—we're talking $506 million in US sales just in Q4 2025 from the newer formulation. Meanwhile, the original Eylea brought in $577 million that same quarter. It's not replacing the old version entirely, but it's clearly helping offset some of the decline.

What's more interesting to me though is the Dupixent story. This drug is firing on all cylinders across multiple indications—atopic dermatitis, asthma, chronic rhinosinusitis, eosinophilic esophagitis, and increasingly in areas like prurigo nodularis where demand is building. Regeneron doesn't record the sales directly since they have a profit-sharing deal with Sanofi, but their share of those profits has been growing noticeably. That's the real offset to any Eylea weakness.

They're also making moves to diversify away from eye care. Libtayo in oncology is ramping up—the label expansions in Europe and approvals for cutaneous squamous cell carcinoma are opening new patient populations. Then there's Lynozyfic, their newly approved multiple myeloma drug, plus Ordspono for lymphomas. These aren't blockbusters yet, but they're building out a legitimate oncology franchise.

One thing investors sometimes overlook: they've been aggressive with share buybacks. In February 2025, they authorized another $3 billion repurchase program. That kind of capital return helps support the bottom line even if top-line growth is moderating in certain areas.

Historically, this company has beaten earnings expectations pretty consistently—about 22% average surprise over the last few quarters. The combination of Dupixent's solid performance and Eylea HD's strong initial traction suggests they're navigating this transition better than some might expect. Worth keeping on your radar if you're looking at healthcare exposure, especially with the diversification they're building into oncology.